Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care

Ontario Industry Updates
Written By Guest User

TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce that Fresenius Medical Care (Frankfurt Stock Exchange: FME and NYSE: FMS), the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).

Click here for the full press release

Guest User
Previous

Self Care Cataysts - Featured Article, Inc. Magazine
Next

Focal Healthcare receives 510(k) clearance from the FDA for their targeted prostate biopsy device, Fusion Bx